{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Williams DW"],"funding":["NIMH","NICHD NIH HHS","NCATS NIH HHS","NIDA NIH HHS","NIA NIH HHS","NIAID NIH HHS","NIMH NIH HHS","NHLBI NIH HHS","NIH","NIH HHS"],"pagination":["181-194"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7430262"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Antiretroviral therapy (ART) is inconsistently associated with depression. These associations may depend on factors such as biological sex, age, and health status. Identifying such factors may help optimize treatment of HIV and depression. We implemented a novel approach to examine interindividual variability in the association between ART agents and depressive symptoms. 3434 women living with HIV (WLWH) from the Women's Interagency HIV Study (WIHS) were computationally divided into subgroups based on sociodemographic (e.g., age) and longitudinal (from 1995 to 2016) behavioral and clinical profiles (e.g., substance use, HIV RNA, CD4 counts). Five subgroups (n's ranged from 482 to 802) were identified and characterized as those with: controlled HIV/vascular comorbidities; profound HIV legacy effects; younger women [<45 years of age] with hepatitis C; primarily 35-55 year olds; and poorly controlled HIV/substance use. Within each subgroup, we examined associations between ART agents used over the past 6 months and item-level depressive symptoms on the Center for Epidemiologic Studies Depression Scale. Tenofovir (4 of 5 subgroups) followed by efavirenz, emtricitabine, stavudine, lopinavir, etravirine, nelfinavir, ritonavir, and maraviroc were the most common agents associated with depressive symptoms, although the pattern and directionality varied by subgroup. For example, lopinavir was associated with fewer symptoms among the subgroup with a legacy HIV effect but more symptoms among the subgroup with well-controlled HIV/vascular comorbidities. Unexpectedly, dolutegravir and raltegravir were not associated with depressive symptoms among any subgroup. Findings underscore marked interindividual variability in ART agents on depression in WLWH. Sociodemographic, clinical, and behavioral factors are important determinants of the relationship between ART agents and depressive symptoms in WLWH. Graphical Abstract Are antiretroviral agents a risk factor for depressive symptoms in women with HIV? We examined associations between ART-agents and depressive symptoms among similar subgroups of women with HIV from the Women's Interagency HIV Study. The patterns of associations depended on sociodemographic, clinical, and behavioral characteristics of women."],"journal":["Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology"],"pubmed_title":["Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV."],"pmcid":["PMC7430262"],"funding_grant_id":["P30 AI050410","U01-AI-103390","U01-AI-031834","UL1 TR000454","R00 DA044838","U01-AI-042590","U01 AI034994","U01 AI034993","UL1-TR000004","U01 AI035004","U01 HL146204","U01-AI-034989","U01-AI-103397","R01 DA052859","U01 AI103401","U01 HL146202","P30-AI-050410","K01 MH121582","R21 AG059505","U01 AI103408","P30 AI094189","P30 AI027767","U01 AI031834","U01 AI034989","U01 AI103397","UL1-TR000454","U01-AI-103401","U01 HD032632","UL1 TR000004","U01-AI-034994","U01-AI-034993","U01-AI-035004","U01 AI103390","U01-AI-103408","U01-HD-032632","P30-AI-027767","U01 AI042590","U01 HL146194","P30MH075773"],"pubmed_authors":["Fischl MA","Spence AB","Adimora AA","Milam J","Li Y","Maki PM","Sharma A","Ofotokun I","Gustafson DR","Rubin LH","Fitzgerald KC","Dastgheyb R","Weber KM","Williams DW","Konkle-Parker D","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.","description":"Antiretroviral therapy (ART) is inconsistently associated with depression. These associations may depend on factors such as biological sex, age, and health status. Identifying such factors may help optimize treatment of HIV and depression. We implemented a novel approach to examine interindividual variability in the association between ART agents and depressive symptoms. 3434 women living with HIV (WLWH) from the Women's Interagency HIV Study (WIHS) were computationally divided into subgroups based on sociodemographic (e.g., age) and longitudinal (from 1995 to 2016) behavioral and clinical profiles (e.g., substance use, HIV RNA, CD4 counts). Five subgroups (n's ranged from 482 to 802) were identified and characterized as those with: controlled HIV/vascular comorbidities; profound HIV legacy effects; younger women [<45 years of age] with hepatitis C; primarily 35-55 year olds; and poorly controlled HIV/substance use. Within each subgroup, we examined associations between ART agents used over the past 6 months and item-level depressive symptoms on the Center for Epidemiologic Studies Depression Scale. Tenofovir (4 of 5 subgroups) followed by efavirenz, emtricitabine, stavudine, lopinavir, etravirine, nelfinavir, ritonavir, and maraviroc were the most common agents associated with depressive symptoms, although the pattern and directionality varied by subgroup. For example, lopinavir was associated with fewer symptoms among the subgroup with a legacy HIV effect but more symptoms among the subgroup with well-controlled HIV/vascular comorbidities. Unexpectedly, dolutegravir and raltegravir were not associated with depressive symptoms among any subgroup. Findings underscore marked interindividual variability in ART agents on depression in WLWH. Sociodemographic, clinical, and behavioral factors are important determinants of the relationship between ART agents and depressive symptoms in WLWH. Graphical Abstract Are antiretroviral agents a risk factor for depressive symptoms in women with HIV? We examined associations between ART-agents and depressive symptoms among similar subgroups of women with HIV from the Women's Interagency HIV Study. The patterns of associations depended on sociodemographic, clinical, and behavioral characteristics of women.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T02:25:06.147Z","creation":"2025-04-04T02:25:06.147Z"},"accession":"S-EPMC7430262","cross_references":{"pubmed":["31933016"],"doi":["10.1007/s11481-019-09899-2"]}}